Ibriturnomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma.

被引：0
|
作者：
Shimoni, A [1 ]
Zwas, T [1 ]
Oksman, Y [1 ]
Hardan, I [1 ]
Shem-Tov, N [1 ]
Yerushalmi, R [1 ]
Avigdor, A [1 ]
Ben-Bassat, I [1 ]
Nagler, A [1 ]
机构：
[1] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1131
引用
收藏
页码：329A / 329A
页数：1
相关论文
共 50 条
  • [1] Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation (SCT) in patients with chemo-refractory now Hodgkin's lymphoma
    Shimoni, A
    Zwass, T
    Oksman, Y
    Hardan, L
    Shem-Tov, N
    Yershalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 119 - 119
  • [2] Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S93 - S93
  • [3] Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem cell transplantation in patients with chemorefractory non-Hodgkin lymphoma
    Shimoni, A
    Zwass, T
    Oksman, Y
    Hardan, I
    Shem-Tov, N
    Yerushalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S234 - S234
  • [4] Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
    A Shimoni
    S T Zwas
    Y Oksman
    I Hardan
    N Shem-Tov
    A Rand
    R Yerushalmi
    A Avigdor
    I Ben-Bassat
    A Nagler
    Bone Marrow Transplantation, 2008, 41 : 355 - 361
  • [5] Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
    Shimoni, A.
    Zwas, S. T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Rand, A.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2008, 41 (04) : 355 - 361
  • [6] Reduced-intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin and non-Hodgkin lymphoma.
    Lerner, D
    Azevedo, AM
    Colares, M
    de Cássia, R
    Tavares, B
    Maradei, SC
    Lima, J
    Lobo, AMG
    Tabak, DG
    Urago, K
    Lima, MC
    Maiolino, A
    Bouzas, LFS
    BLOOD, 2005, 106 (11) : 443B - 443B
  • [7] Reduced-intensity conditioning allogeneic stem cell transplantation for patients with refractory or relapsed non-Hodgkin lymphoma
    De Lavallade, H.
    Bouabdallah, R.
    Faucher, C.
    Furst, S.
    El Cheikh, J.
    Vey, N.
    Stoppa, A. M.
    Sainty, D.
    Arnoulet, C.
    Xerri, L.
    Cassier, P.
    Gastaut, J. A.
    Blaise, D.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S149 - S149
  • [8] Ibritumomab tiuxetan combined with high-dose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Nagler, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [9] REDUCED-INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN'S AND NON-HODGKIN'S LYMPHOMA
    Gutierrez-Aguirre, C. H.
    Cantu-Rodriguez, O. G.
    Gonzalez-Llano, O.
    Jaime-Perez, J. C.
    Salazar-Riojas, R.
    Martinez-Gonzalez, O. L.
    Gutierrez-Riverol, K. I.
    Ruiz-Delgado, G. J.
    Ruiz-Arguelles, G. J.
    Gomez-Almaguer, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 67 - 67
  • [10] Feasibility of allogeneic hematopoietic stem cell transplantation (HSCT) with a reduced-intensity (RI) conditioning regimen for non-Hodgkin's lymphoma (NHL).
    Kusumi, E
    Tanimoto, TE
    Kami, M
    Hamaki, T
    Yuji, K
    Ueyama, J
    Miyakoshi, S
    Morinaga, S
    Kanda, Y
    Makimoto, A
    Kataoka, I
    Kim, SW
    Ohnishi, M
    Nakai, K
    Tobinai, K
    Tanosaki, R
    Mineishi, S
    Takaue, Y
    Mutou, Y
    BLOOD, 2001, 98 (11) : 377B - 377B
12345